AngioDynamics Inc

Stage 2 advancing structure and active Momentum Breakout pattern confirm a bullish medium/long-term bias; however, price is extended above the short-term EMA band and in extreme overbought territory, making immediate execution unfavorable. Optimal engagement is deferred into pullbacks toward rising EMA support and prior resistance zones.

• ↑MedTech segment grew 19% YoY, comprising 47% of total revenue
• ↑Projected gross margins of 54%–55% in fiscal 2027 support profitability
• ↓Over 350 catheter lawsuits pose material financial and operational risk